CL2019001344A1 - Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo. - Google Patents
Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo.Info
- Publication number
- CL2019001344A1 CL2019001344A1 CL2019001344A CL2019001344A CL2019001344A1 CL 2019001344 A1 CL2019001344 A1 CL 2019001344A1 CL 2019001344 A CL2019001344 A CL 2019001344A CL 2019001344 A CL2019001344 A CL 2019001344A CL 2019001344 A1 CL2019001344 A1 CL 2019001344A1
- Authority
- CL
- Chile
- Prior art keywords
- preparing
- preventing
- pharmaceutical composition
- same
- crystalline polymorph
- Prior art date
Links
- UYVQXFOBKTWZCW-UHFFFAOYSA-N tetraarsenic Chemical compound [As]12[As]3[As]1[As]32 UYVQXFOBKTWZCW-UHFFFAOYSA-N 0.000 title abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G28/00—Compounds of arsenic
- C01G28/005—Oxides; Hydroxides; Oxyacids
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/60—Compounds characterised by their crystallite size
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/80—Compositional purity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
COMPOSICION FARQMCEUTICA QUE CONTIENE HEXOXIDO TETRAARSENICO EN UN 99% O MAS DE POLIMORFO CRISTALINO; METODO PARA PREPARAR EL COMPUESTO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160154409A KR101755556B1 (ko) | 2016-11-18 | 2016-11-18 | 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001344A1 true CL2019001344A1 (es) | 2020-02-21 |
Family
ID=59353596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001344A CL2019001344A1 (es) | 2016-11-18 | 2019-05-16 | Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10493100B2 (es) |
| EP (1) | EP3542804B1 (es) |
| JP (1) | JP6824431B2 (es) |
| KR (1) | KR101755556B1 (es) |
| CN (1) | CN108066358B (es) |
| AU (1) | AU2017360407B2 (es) |
| BR (1) | BR112019009810A2 (es) |
| CA (1) | CA3043145C (es) |
| CL (1) | CL2019001344A1 (es) |
| IL (1) | IL266660B (es) |
| MX (1) | MX391742B (es) |
| MY (1) | MY196811A (es) |
| PH (1) | PH12019501110A1 (es) |
| SA (1) | SA519401787B1 (es) |
| WO (1) | WO2018093029A1 (es) |
| ZA (1) | ZA201902611B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN108066359A (zh) * | 2016-11-09 | 2018-05-25 | 凯马斯株式会社 | 包含六氧化四砷的用于抑制癌转移的药物组合物 |
| KR101755556B1 (ko) | 2016-11-18 | 2017-07-07 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
| KR101834366B1 (ko) * | 2016-11-21 | 2018-03-05 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
| KR101844049B1 (ko) * | 2016-12-05 | 2018-03-30 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물 |
| KR101844050B1 (ko) | 2016-12-09 | 2018-05-14 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US20230149452A1 (en) * | 2020-04-06 | 2023-05-18 | Yogesh BENDALE | Structurally defined, better tolerated, orally adminstered, processed arsenolite, a process for its preparation, a pharmaceutical composition and uses thereof |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| KR20250118232A (ko) | 2024-01-29 | 2025-08-05 | 배일주 | 육산화사비소(As4O6)를 포함하는 방광암 예방 또는 치료용 약학 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7261906B2 (en) * | 1998-05-08 | 2007-08-28 | Ill-Ju Bae | Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition |
| KR100272835B1 (ko) * | 1998-05-08 | 2000-11-15 | 배일주 | 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물 |
| KR100399657B1 (ko) * | 2000-06-29 | 2003-09-29 | 배일주 | 혈관신생 억제제 |
| KR20020095835A (ko) * | 2001-06-16 | 2002-12-28 | 배일주 | 아폽토시스 유도제 |
| CN1471925A (zh) * | 2002-08-02 | 2004-02-04 | 丛繁滋 | 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法 |
| TWI296527B (en) * | 2003-04-23 | 2008-05-11 | Inst Of Nuclear Energy Res Rocaec | Radioactive aesenic-containing compounds and their uses in the treatment of tumors |
| US20060046993A1 (en) * | 2004-09-01 | 2006-03-02 | Pharmacia Italia S.P.A. | Crystalline polymorphic form of irinotecan hydrochloride |
| EP2249844A1 (en) * | 2008-03-12 | 2010-11-17 | Ludwig-Maximilians-Universität München | Active substance combination with gemcitabine for the treatment of epithelial cancer |
| KR101572529B1 (ko) | 2008-11-14 | 2015-11-27 | 배일주 | 암 치료를 위한 육산화사비소의 병용요법 |
| KR101100786B1 (ko) * | 2008-12-16 | 2011-12-29 | (주)천지산 | 암에 대한 방사선 치료 증진용 조성물 |
| KR101119587B1 (ko) | 2011-03-10 | 2012-04-17 | 배일주 | 육산화사비소를 함유하는 용출률 및 안정성이 개선된 경구투여형 약제학적 제제 |
| KR101755556B1 (ko) | 2016-11-18 | 2017-07-07 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
-
2016
- 2016-11-18 KR KR1020160154409A patent/KR101755556B1/ko active Active
-
2017
- 2017-01-24 CN CN201710060263.5A patent/CN108066358B/zh active Active
- 2017-09-07 JP JP2019547051A patent/JP6824431B2/ja active Active
- 2017-09-07 AU AU2017360407A patent/AU2017360407B2/en active Active
- 2017-09-07 WO PCT/KR2017/009820 patent/WO2018093029A1/ko not_active Ceased
- 2017-09-07 CA CA3043145A patent/CA3043145C/en active Active
- 2017-09-07 MY MYPI2019002666A patent/MY196811A/en unknown
- 2017-09-07 MX MX2019005737A patent/MX391742B/es unknown
- 2017-09-07 BR BR112019009810A patent/BR112019009810A2/pt not_active Application Discontinuation
- 2017-09-07 US US16/461,892 patent/US10493100B2/en active Active
- 2017-09-07 EP EP17872515.6A patent/EP3542804B1/en active Active
-
2019
- 2019-04-25 ZA ZA201902611A patent/ZA201902611B/en unknown
- 2019-05-14 SA SA519401787A patent/SA519401787B1/ar unknown
- 2019-05-15 IL IL266660A patent/IL266660B/en unknown
- 2019-05-16 CL CL2019001344A patent/CL2019001344A1/es unknown
- 2019-05-17 PH PH12019501110A patent/PH12019501110A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019005737A (es) | 2019-07-04 |
| US20190328779A1 (en) | 2019-10-31 |
| CA3043145C (en) | 2021-11-09 |
| WO2018093029A1 (ko) | 2018-05-24 |
| US10493100B2 (en) | 2019-12-03 |
| IL266660B (en) | 2021-09-30 |
| AU2017360407A1 (en) | 2019-06-20 |
| CA3043145A1 (en) | 2018-05-24 |
| BR112019009810A2 (pt) | 2019-08-13 |
| EP3542804A1 (en) | 2019-09-25 |
| MY196811A (en) | 2023-05-03 |
| CN108066358A (zh) | 2018-05-25 |
| PH12019501110A1 (en) | 2020-03-02 |
| AU2017360407B2 (en) | 2020-11-26 |
| CN108066358B (zh) | 2021-06-25 |
| MX391742B (es) | 2025-03-21 |
| JP6824431B2 (ja) | 2021-02-03 |
| EP3542804B1 (en) | 2021-11-03 |
| IL266660A (en) | 2019-07-31 |
| ZA201902611B (en) | 2020-11-25 |
| JP2020500219A (ja) | 2020-01-09 |
| EP3542804A4 (en) | 2020-05-27 |
| KR101755556B1 (ko) | 2017-07-07 |
| SA519401787B1 (ar) | 2021-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001344A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo. | |
| CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2024012899A (es) | Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias | |
| CL2019001369A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| MX2021006571A (es) | Inhibidores de tirosina-cinasas. | |
| DOP2017000048A (es) | Compuestos aminopirimidinilo como inhibidores de jak. | |
| CO2017002191A2 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| UY36419A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX2017000170A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
| MX2016010216A (es) | Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos. | |
| BR112017007063A2 (pt) | ?composições e métodos para o tratamento de insônia? | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| CL2019000661A1 (es) | Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica. | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. |